Sterling Pharma Solutions unveils $13.4 million investment plan for Dudley, UK site
Financial commitment expected to increase plant's process development and manufacturing capacity
Sterling Pharma Solutions, a contract development and manufacturing organization (CDMO), has introduced the next phase of its multi-year investment strategy at its location in Dudley, UK. The $13.4 million plan will include the building and commissioning of new process development laboratories, and the installation of additional commercial-scale manufacturing equipment, in order to address the growth in demand for small molecule active pharmaceutical ingredient (API) manufacturing.
The project—which has an anticipated completion date of mid-2022—features the installation of a 4.5 cubic-meter (159 cubic-foot) hydrogenator, that is capable of pressure reactions up to 10 bar, along with supplemental conical and filter dryers within the current manufacturing plant. The CDMO's new kilo-scale and technology laboratories will be built in the site’s Material Science Centre, which was constructed as an earlier part of the investment strategy in 2020.
“The next phase of our strategic plan is to increase and enhance our capacity to develop and scale up processes for commercial readiness, and is [a] testament to the continued, strong interest that we are seeing in small molecule development,” says Kevin Cook, Sterling’s CEO.
